Inhibitory Effect of a Novel Orally Active GP IIb/IIIa Inhibitor, SC-54684A on Intimal Thickening in the Guinea Pig Femoral Artery

Summary

The inhibitory effect of a novel orally active platelet membrane glycoprotein receptor complex IIb/IIIa (GP IIb/IIIa) inhibitor, SC-54684A is studied on intimal thickening in the guinea pig femoral artery. A segment of the femoral artery was occluded by a platelet-rich thrombus induced by photochemical reaction between systemically administered Rose Bengal and transluminal green light which causes endothelial injury followed by platelet adhesion and aggregation at the site of photochemical reaction. Three weeks after successful thrombolysis by tissue-type plasminogen activator, intimal thickening occurred at the irradiated site. SC-54684A (30 mg/kg), administered 2 h before photochemical reaction, significantly (P <0.05) prolonged the time to occlusion of the femoral artery; in this respect aspirin (100 mg/kg) was ineffective. A combination of SC-54684A and recombinant tissue-type plasminogen activator (rt-PA) increased the frequency of reopening and significantly (P <0.05) prolonged the duration of reflow compared with rt-PA alone. Further, SC-54684A administered orally twice a day for 3 weeks significantly (P <0.05) inhibited intimal thickening but aspirin, administered orally once a day for 3 weeks, was ineffective. Scanning electron microscopy revealed extensive platelet adhesion and aggregation on the denuded vessel walls in the untreated group 24 h after successful thrombolysis. In separate experiments, SC-54684A markedly inhibited platelet aggregation ex-vivo. Inhibition of platelet adhesion and aggregation at the site of endothelial injury by SC-54684A (via GPIIb/IIIa inhibition) may account for its inhibitory effect on intimal thickening

• References

• 1 Serruys PW, Luijten HE, Beat KJ, Geuskens R, Defeyter PJ, Van den Brand M, Reiber JHC, Tenkaten HJ, Vanes GA, Hugenholtz PG. Incidence of restenosis after successful coronary angioplasty: A time-related phenomenon: A quantitative angiographic study in 342 consecutive patients at 1,2,3 and 4 months. Circulation 1988; 77: 361-371
• 2 Kaltenbach M, Kober G, Scherer D, Vallbracht C. Recurrence rate after successful coronary angioplasty. Eur Heart J 1985; 6: 276-281
• 3 White CW, Knudson M, Schmidt D, Chisholm RJ, Vandormael M, Morton B, Roy L, Khaja F, Reitman M. Neither ticlopidine nor aspirin-dipyrida-mole prevents restenosis post PTCA. Circulation 1987; 76 (Suppl. 04) IV-213
• 4 Thornton MA, Gruentzig AR, Hollman J, King SB, Douglas JS. Coumadin and aspirin in prevention of recurrence after transluminal coronary angioplasty: a randomized study. Circulation 1984; 69: 721-727
• 5 Kent KM, Bentivoglio JG, Block PC, Cowley MJ, Dorros G, Gosselin AJ, Myler RK, Simpson J, Williams DO, Fisher L, Gillespie MJ, Kelsey S, Mullin SM, Mock MB. Percutaneous transluminal coronary angioplasty: report from the registry of the National Heart, Lung and Blood Institute. Am J Cardiol 1982; 49: 2011-2020
• 6 Clowes AW, Reidy MA, Clowes MM. Mechanisms of stenosis after arterial injury. Lab Invest 1983; 43: 208-215
• 7 Herbert JM, Tissinier A, Defreyn G, Maffrand JP. Inhibitory effect of clo-pidogrel on platelet adhesion and intimal proliferation after arterial injury in rabbits. Arterioscler Thromb 1993; 13: 1171-1179
• 8 Ross R. The pathogenesis of atherosclerosis: an update. N Engl J Med 1986; 314: 488-500
• 9 Liu MW, Roubin GS, King SB. Restenosis after coronary angioplasty: Potential biologic determinants and role of intimal hyperplasia. Circulation 1989; 79: 1374-1387
• 10 Bennett JS, Vilaire G. Exposure of platelet fibrinogen receptors by ADP and epinephrine. J Clin Invest 1979; 64: 1393-1401
• 11 Marguerie GA, Edington TS, Plow EF. Interaction of fibrinogen with its platelet receptor as part of a multistep reaction in ADP-induced platelet aggregation. J Biol Chem 1980; 255: 154-161
• 12 Gold HK, Coller BS, Yasuda T, Saito T, Fallon JT, Guerrero JL, Leinbach RC, Ziskind AA, Collen D. Rapid and sustained coronary artery recanalization with combined bolus injection of recombinant tissue-type plasminogen activator and monoclonal antiplatelet GPIIb/IIIa antibody in a canine preparation. Circulation 1988; 77: 670-677
• 13 Mickelson JK, Simpson PJ, Cronin M, Homeister JW, Lay well E, Kitzen J, Lucchesi BR. Antiplatelet antibody [7E3 F(ab’)2] prevents rethrombosis after recombinant tissue-type plasminogen activator-induced coronary artery thrombolysis in a canine model. Circulation 1990; 81: 617-627
• 14 Yasuda T, Gold HK, Leinbach RC, Saito T, Guerrero JL, Jang IK, Holt R, Fallon JT, Collen D. Lysis of plasminogen activator-resistant platelet-rich coronary artery thrombus with combined bolus injection of recombinant tissue-type plasminogen activator and antiplatelet GPIIb/IIIa antibody. J Am Coll Cardiol 1990; 16: 1728-1735
• 15 Nicholson NS, Panzer-Knodle SG, Salyers AK, Taite BB, Szalony JA, Haas NF, King LW, Zablocki JA, Keller BT, Broschat K, Engleman VW, Herin M, Jacqmin P, Feigen LP. SC-54684A: an orally active inhibitor of platelet aggregation. Circulation 1995; 91: 403-410
• 16 Szalony JA, Haas NF, Salyers AK, Taite BB, Nicholson NS, Mehrotrs DV, Feigen LP. Extended inhibition of platelet aggregation with the orally active platelet inhibitor SC-54684A. Circulation 1995; 91: 411-416
• 17 Topol EJ, Califf RM, Weisman HF, Elli SG, Tcheng JE, Worley S, Ivanhoe R, George BS, Fintel D, Weston M, Sigmon K, Anderson KM, Lee KL, Willerson JT. on behalf of the EPIC investigators. Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. Lancet 1994; 343: 881-886
• 18 The EPIC investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994; 330: 956-961
• 19 Hirata Y, Umemura K, Kondoh K, Uematsu T, Nakashima M. Experimental intimal thickening studies using the photochemically induced thrombosis model in the guinea-pig femoral artery. Atherosclerosis 1994; 107: 117-124
• 20 Saniabadi AR. Photosensitisers and photochemical reactions. In: A novel photochemical model for thrombosis research and evaluation of antithrombotic and thrombolytic agents, pp 1-19 Nakashima M. ed. Churchill Livingstone: 1994
• 21 Hirata Y, Takiguchi Y, Wada K, Matsuno H, Umemura K, Uematsu T, Nakashima M. Roles of TXA₂, platelet-activating factor, ADP and thrombin in thrombogenesis in the guinea pig. Eur J Pharmacol 1993; 231: 421-425
• 22 Saniabadi AR, Umemura K, Matsumoto S, Sakuma S, Nakashima M. Arterial thrombosis initiated by photochemical reaction: a consequence of vessel wall injury. Thromb Haemost 1995; 73: 868-872
• 23 Fitzgerald DJ, Catella F, Roy F, FitzGerald GA. Marked platelet activation in vivo after intravenous streptokinase in patients with acute myocardial infarction. Circulation 1988; 77: 142-150
• 24 Nishiyama H, Umemura K, Saniabadi AR, Takiguchi Y, Uematsu T, Nakashima M. Enhancement of thrombolytic efficacy of tissue-type plasminogen activator by ajuvants in the guinea pig thrombosis model. Eur J Pharmacol 1994; 264: 191-198
• 25 Ross R, Raines EW, Bowen-Pope DF. The biology of platelet derived-growth factor. Cell 1986; 46: 155-169
• 26 Ferns GA, Raines EW, Sprugel KH, Motani AS, Reidy MA, Ross R. Inhibition of neointimal smooth muscle accumulation after anigioplasty by an antibody to PDGF. Science 1991; 253: 1129-1131
• 27 Hung DL, Latus LJ, Lev-Ran A. Effects of platelet-contained growth factors (PDGF, EGF, IGF-1, and TGF-beta) on DNA synthesis in porcine aortic smooth muscle cell in culture. Exp Cell Res 1992; 200: 358-360
• 28 Clegg KB, Sambhi M. Inhibition of epidermal growth factor-mediated DNA synthesis by a specific tyrosine kinase inhibitor in vascular smooth muscle cells of the spontaneously hypertensive rat. J Hypertens 1989; 7 (Suppl. 06) S144-S145
• 29 Nemecek GM, Coughlin SR, Handley DA, Moskowitz MA. Stimulation of aortic smooth muscle cell mitogenesis by serotonin. Proc Natl Acad Sci USA 1986; 83: 674-678
• 30 Pakala R, Willerson JT, Benedict CR. Mitogenic effect of serotonin on vascular endothelial cells. Circulation 1994; 90: 1919-1926
• 31 Panettieri RA, Yadvish PA, Kelly AM, Rubenstein NA, Kotlikoff MI. Histamine stimulates proliferation of airway smooth muscle and induces c-fos expression. Am J Physiol 1990; 259: L365-L371
• 32 Issandou M, Darbon J-M. Ses-arg⁹ bradykinin modulates DNA synthesis, phospholipase C, and protein kinase C in cultured mesangial cells: distinction from effects of bradykinin. J Biol Chem 1991; 31: 21037-21043
• 33 Nigata T, Uehara Y, Numabe A, Ishimitsu T, Hirawa N, Ikeda T, Matsuoka H, Sugimoto T. Regulatory effect of thromboxane A₂ on proliferation of vascular smooth muscle cells from rats. Am J Physiol 1992; 263: H1331-H1338
• 34 Wang D, Hung H, Heppel LA. Extracellular ATP and ADP stimulate proliferation of porcine aortic smooth muscle cells. J Cell Physiol 1992; 153: 221-233
• 35 Nakaki T, Nakayama M, Yamamoto S, Kato R. α₁-adrenergic stimulation and β₂-adrenergic inhibitor of DNA synthesis in vascular smooth muscle cells. Mol Pharmacol 1990; 37: 30-36
• 36 Matsuno H, Stassen JM, Hoylaerts MF, Bunting S, Vermylen J, Deckmyn D. Correlation between initial thrombus size and neointima formation in the damaged hamster carotid artery (in abstract). Thromb Haemost 1995; 73: 911
• 37 Choi ET, Engel L, Callow AD, Sun S, Trachtenberg J, Santoro S, Ryan US. Inhibition of neointimal hyperplasia by blocking α_vβ₃ integrin with a small peptide antagonist Gpen GRGDSPCA. J Vase Surg 1994; 19: 125-134
• 38 Matsuno H, Vermylen J, Deckmyn H. Inhibition of integrin function by a cyclic RGD-containing peptide prevents neointima formation. Circulation 1994; 90: 2203-2206
• 39 Sakariassen KS, Bolhuis PA, Sixma JJ. Human blood platelet adhesion to artery subendothelium is mediated by factor VUI-von Willebrand factor bound to the subendothelium. Nature 1979; 279: 636
• 40 Coller BS, Peerschke EI, Scudder LE, Sullivan CA. Studies with a murine antibody that abolishes ristocetin-induced binding of von Willebrand factor to platelets: Additional evidence in support of GPIb as a platelet receptor for vWF. Blood 1983; 61: 99-110
• 41 Sheppeck RA, Bentz M, Dickson C, Hribar S, White J, Janosky J, Berceli SA, Borovetz HS, Johnson PC. Examination of the roles of glycoprotein lb and glycoprotein IIb/IIIa in platelet deposition on an artificial surface using clinical antiplatelet agents and monoclonal antibody blockade. Blood 1991; 78: 673-680
• 42 Aleviradou BR, Moske JL, Tuner NA, Ruggeri ZM, Folie BJ, Phillips MD, Schreiber AB, Hirda ME, Mclntire LV. Real-time analysis of shear-dependent thrombus formation and its blockade by inhibitors of von Willebrand factor binding to platelets. Blood 1993; 81: 1263-1276